DOCSLIB.ORG

Supplemental Material Gut Doi: 10.1136/Gutjnl-2020-323476 –11. :10 2021; Gut , Et Al. Chen F

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplemental Material Gut Doi: 10.1136/Gutjnl-2020-323476 –11. :10 2021; Gut , Et Al. Chen F BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Gut Table S2. List of colorectal abnormal associated metabolites Metabolite feature Metabolite annotation approach F_meanN F_meanC F_meanA anova_nc_adj anova_na_adj anova_ca_adj F_cvNp_raw_log2F_cvCp_raw_log2 F_fc_nc_raw F_fc_na_raw F_fc_ac_raw X10.3_339.237mz_pos (-)-Folicanthine exact mass match 7748.846605 5053.536056 5527.387681 0.00000527 7.36E-08 0.016360165 1.066485107 3.045501184 0.732979425 0.686815097 1.067215076 X12.4_340.269mz_pos (-)-Ormosanine exact mass match 45226.06503 31316.75757 27721.72218 0.00000798 0.0000327 0.374105369 0.82512597 0.830862497 0.687636808 0.562694393 1.222043114 X10.9_313.166mz_neg (-)-trans-Carveol glucosideexact mass match 364.3974089 8542.0151 9965.786895 0.002652316 0.000960176 0.295523934 7.802344415 1.555479803 8.146636736 8.049968526 1.01200852 X15_265.108mz_neg (+)-2,5-epi Goniothalesdiolexact mass match 32595.35307 22986.25282 25975.3202 0.001250629 0.001302286 0.43224324 1.276557314 2.675216985 0.752619218 0.720752853 1.04421261 X20.8_388.119mz_neg (+/-)-6-Acetonyldihydrosaexact mass match 6812.396901 10133.51548 3573.206732 0.004217867 0.0002535 0.116465099 6.234319405 7.015515802 1.484891164 0.526968596 2.817798206 X12.5_321.241mz_pos (±)15-HETE exact mass match 11931.10675 8063.355578 8309.938888 3.99E-10 3.99E-10 0.00389225 1.0537419 2.554831014 0.707014986 0.657446626 1.075395262 X14.9_265.108mz_neg (±)-Goniothalesdiol exact mass match 24851.58866 16540.4257 15696.90897 0.002211296 0.000178788 0.127514798 0.650486116 0.819995262 0.718165912 0.582429257 1.233052604 X15.1_333.226mz_pos (±)-Pandamarine exact mass match 78154.92166 37693.09503 61456.22917 0.00000158 0.000472756 0.950049258 1.398514317 1.360676174 0.471657455 0.682169628 0.691407878 X24_357.235mz_neg (1S)-1-hydroxy-23-oxo-24exact mass match 2067.046116 6783.212071 10613.37145 0.00000682 0.00010632 0.584324567 2.877609538 13.07421455 2.452112148 3.00547459 0.815881843 X20.7_645.438mz_pos (20R)-Ginsenoside Rh2 exact mass match 19519.16483 12756.37371 12327.32875 4.39E-10 4.01E-10 0.003733196 1.465309488 2.612138841 0.666444891 0.589918254 1.129724137 X11_428.321mz_pos (22E)-1α-hydroxy-24-oxo-26,27-cyclo-22,23-didehydrovitaminexact mass match 97120.90614 D3 72845.20464/ (22E)-1α-hydroxy-24-oxo-26,27-cyclo-22,23-didehydrocholecalciferol 62220.94605 3.99E-10 3.99E-10 0.0064595 0.841975269 0.930335036 0.716145838 0.559366987 1.280279057 X12.4_546.383mz_pos (22S)-Acetoxy-3alpha,15alpexact mass match 9231.270141 6429.061705 6092.236396 0.0000161 0.0000601 0.397096351 1.227501645 3.258940702 0.743957672 0.630497745 1.179952946 X18.7_445.296mz_neg (23S,25R)-1α,25-dihydroxyvitaminexact mass D3 match26,23-lactol / (23S,25R)-1α,25-dihy 19031.02292 32357.61626droxycholecalciferol 37626.34194 26,23-lactol 0.0000078 0.001813676 0.985522683 0.507675713 0.769683063 1.729323187 1.728930055 1.000227384 X4.8_524.344mz_pos (25R)-3alpha,7alpha-dihydrexact mass match 42278.66705 14322.95252 13266.55609 0.000000306 0.000571753 0.999569714 1.459558199 4.480875598 0.342545041 0.286060852 1.197455154 X9_530.336mz_pos (25S)-11alpha,20,26-trihydrexact mass match 38023.71975 26906.34985 25382.98412 3.99E-10 4E-10 0.022765966 0.916553919 2.051186976 0.708744036 0.614803877 1.152796954 X12.2_502.357mz_pos (25S)-3-oxo-12beta-acetoxyexact mass match 31958.1137 23103.82901 21531.79709 4.03E-10 3.99E-10 0.003719973 0.682227397 1.154315774 0.722037656 0.619163391 1.166150433 X11.6_286.201mz_pos (2E)-octenoylcarnitine MS/MS spectrum match 13453.00627 33364.91448 33905.72166 0.000017 0.002253687 0.971075742 4.188632551 2.955775791 2.306003701 2.18233241 1.056669318 X20.3_715.487mz_pos (2'S)-Deoxymyxol 2'-α-L-fucosideexact mass match 7748.409131 5609.9888 3555.197895 0.0000691 0.00000981 0.104453542 4.288444982 7.967021716 0.788635377 0.463329937 1.702103218 X18.1_587.394mz_pos (3b,16a,21b,22a)-12-Oleanexact mass match 10628.13143 7185.808936 5500.136528 0.00000153 1.32E-08 0.009300059 4.374952618 5.498801314 0.718968946 0.50677689 1.418709022 X12.2_364.232mz_pos (3S,4S)-3-hydroxytetradecexact mass match 15772.88487 35269.11483 37464.98325 0.00000016 0.000855232 0.964062627 7.835010397 3.687203575 2.089298558 2.068529643 1.010040424 X10.7_400.29mz_pos (3S,5R,6R)-3,5-dihydroxy-6exact mass match 21795.06161 12037.97684 12218.58863 0.000342243 0.00000602 0.037985192 1.595370636 2.189918456 0.5725328 0.5305283 1.079174853 X13_421.295mz_pos (4R,4aS,6aS,8R,9R,11aR,11bSexact mass match 11934.10061 8360.047954 6466.344251 4.19E-10 1.65E-09 0.183096218 1.699455832 2.957412625 0.730073449 0.522233108 1.397983848 X14.7_442.337mz_pos (5E)-(24R)-24,25-dihydroxyexact mass match 49108.46688 36348.05832 29371.42209 4.11E-10 5.26E-08 0.684818542 1.027109275 1.550868479 0.727598766 0.547509065 1.328925515 X22.2_445.311mz_pos (6R)-6-methylvitamin D3 6exact mass match 4926.046547 2706.184577 3686.166487 6.53E-08 0.0000379 0.872966193 2.26998756 12.96484117 0.689016018 0.705749569 0.976289676 X25.6_449.311mz_pos (6R)-vitamin D3 6,19-sulfuexact mass match 12298.18161 7151.685256 9522.914069 4.2E-10 0.0000248 0.801573237 8.812450938 14.90745789 0.618853611 0.718597583 0.861196343 X27.8_353.212mz_neg (E)-2-(4,8-dimethylnona-3MS/MS spectrum match 148979.4135 661207.0536 1133916.741 3.99E-10 3.99E-10 0.134267366 1.84115847 2.063421286 4.322471299 6.715949892 0.643612798 X15.8_555.713mz_pos (Galβ1-4[Fucα1-3]GlcNAcβ)2-Spexact mass match 6637.175039 4303.392169 2880.885392 0.000108407 4.14E-10 0.00000233 7.311820369 14.74482608 0.741581349 0.443439817 1.672338207 X15.8_511.018mz_pos (N-Sulfoindol-3-yl)methylgexact mass match 29186.40004 22499.90694 18837.38392 3.6E-09 1.38E-09 0.02828573 0.807437688 1.75709615 0.768422291 0.59427491 1.293041786 X19.1_542.03mz_pos (R)-AM1241 exact mass match 13839.90492 10689.70452 11501.07819 0.000187398 0.0000275 0.124521706 1.540117563 1.51315139 0.791771246 0.776948566 1.01907807 X10.3_505.194mz_pos (S)-Multifidol 2-[apiosyl-(1exact mass match 10268.06979 14535.29099 8224.276358 0.0000304 0.0000435 0.292377603 3.615316308 4.012332721 1.382979398 0.743269311 1.860670657 X17.5_470.368mz_pos (Z)-2-pentacos-16-enamidexact mass match 1541720.215 1112842.585 1113302.922 4.17E-10 6.75E-08 0.685039559 0.869028884 1.211919695 0.665229088 0.654200409 1.016858258 X15.7_456.352mz_pos (Z)-2-tetracos-15-enamidexact mass match 914827.0994 669049.7222 578207.027 3.99E-10 3.99E-10 0.032418565 0.418785076 0.873093345 0.66058611 0.539320574 1.224848712 X14.3_329.233mz_neg (Z)-5,8,11-trihydroxyoctadeMS/MS spectrum match 23391.65438 4700.138831 6893.331033 3.99E-10 4.06E-10 0.998593315 0.734687355 2.734289476 0.264405313 0.298388796 0.886110057 X26.3_514.705mz_pos [des-Gly-NH29, Arg8]-Vasexact mass match 58954.23862 47623.94754 31991.28776 1.72E-09 3.99E-10 0.00000488 0.887991852 2.109944 0.786544048 0.494575448 1.590341881 X7.4_461.196mz_pos {6-Acetoxy-7-(chloromethexact mass match 12066.52463 17821.67127 7037.00706 0.00000921 5.19E-09 0.001743429 12.56187005 8.351417788 1.436937087 0.553086768 2.598031938 X22.1_471.004mz_pos 1-(2,4-Dichlorophenyl)-2-exact mass match 56381.39632 44502.78039 30959.61396 4.14E-10 3.99E-10 0.000657242 0.969642274 1.655607854 0.769882315 0.50166789 1.534645392 X26.2_848.629mz_pos 1-(2E,6E-phytadienyl)-2-(2exact mass match 391197.9318 272991.3841 220232.0235 3.99E-10 3.99E-10 0.001260118 0.321296523 1.59319371 0.651961453 0.484717969 1.345032564 X7.2_744.501mz_pos 1-(6-[5]-ladderane-hexanoyexact mass match 58212.88359 20344.06023 16941.07618 5.8E-10 0.000000293 0.688047446 1.116039125 2.349430668 0.35885376 0.269034778 1.333856397 X16.7_778.551mz_pos 1-(8-[5]-ladderane-octanoyexact mass match 284763.3151 198505.2832 176867.2336 3.99E-10 3.99E-10 0.006982728 0.295853122 1.130526924 0.645267598 0.539044479 1.197058171 X16.5_822.578mz_pos 1-(8-[5]-ladderane-octanyexact mass match 33376.57516 22110.9712 19406.84485 3.99E-10 3.99E-10 0.013617049 0.303285778 1.504875559 0.668207154 0.539273705 1.239087217 X22.9_715.519mz_pos 1-(O-alpha-D-glucopyranexact mass match 50245.21063 38147.52833 36806.61214 1.61E-09 1.64E-09 0.047439362 1.84759725 1.955617727 0.737649139 0.654686491 1.126721185 X17.9_775.54mz_pos 1,2 di-(9Z,12Z,15Z-octadeexact mass match 89183.85876 60018.2244 69117.56912 3.99E-10 3.99E-10 0.001776808 1.414861814 1.385130578 0.639182096 0.670567659 0.95319553 X15.9_447.806mz_pos 1,2,3,4,6,7,8-Heptachlorodexact mass match 7098.001182 4970.489235 5209.674882 0.000000106 1.97E-09 0.008199487 0.761805982 4.028440188 0.782156344 0.704316829 1.110517756 X6.8_326.253mz_pos 1,2,3-Tris(1-ethoxyethoxy)exact mass match 143458.3827 101128.6631 91529.16404 3.99E-10 4E-10 0.211597027 1.193022627 1.488043386 0.663452782 0.550567111 1.20503526 X8.6_208.073mz_pos 1,2,4-Triazolo[4,3-a]pyridinexact mass match 15083.93153 8850.525113 11917.94535 0.000259009 0.001530194 0.662066759 2.190461061 2.322421687 0.629665027 0.704246466 0.894097531 X20.1_723.486mz_pos 1,26-Dicaffeoylhexacosaneexact mass match 176311.9344 121292.8809 156319.0252 3.99E-10 3.99E-10 0.077374897 1.727010774 2.550051883 0.643955358 0.769519291 0.836828089 X28.5_150.002mz_neg 1,2-Benzisothiazol-3(2H)-onexact mass match 14441.17101 90295.82037 106319.3668 3.99E-10 4.97E-10 0.333541554 1.113873426 1.142490098 5.994711572 6.283797138 0.953995083 X15.7_287.186mz_neg 1,2-Dihexanoyl-sn-glycerolexact mass match 6336.906579 3559.391053 4594.014677 0.000176849 0.000596874 0.52531918 1.127243807
Load more

Recommended publications
  • Eg Phd, Mphil, Dclinpsychol
    This thesis has been submitted in fulfilment of the requirements for a postgraduate degree (e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following terms and conditions of use: • This work is protected by copyright and other intellectual property rights, which are retained by the thesis author, unless otherwise stated. • A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. • This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author. • The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author. • When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given. Equine laminitis pain and modulatory mechanisms at a potential analgesic target, the TRPM8 ion channel Ignacio Viñuela-Fernández Thesis presented for the degree of Doctor of Philosophy The College of Medicine and Veterinary Medicine The University of Edinburgh 2011 DECLARATION I hereby declare that the composition of this thesis and the work presented are my own, with the exception of the ATF-3 and NPY immunohistochemistry which was carried out by Emma Jones. The contribution of others is also appropriately credited. Some of the data included in this thesis have been published and are included in the Appendix. Ignacio Viñuela-Fernández i ACKNOWLEDGEMENTS This work was supported by a Scholarship from the Royal (Dick) Veterinary School at Edinburgh University. I would like to thank Professor Sue Fleetwood- Walker and Dr Rory Mitchell for their supervision, support and guidance throughout my PhD.
    [Show full text]
  • Phytochem Referenzsubstanzen
    High pure reference substances Phytochem Hochreine Standardsubstanzen for research and quality für Forschung und management Referenzsubstanzen Qualitätssicherung Nummer Name Synonym CAS FW Formel Literatur 01.286. ABIETIC ACID Sylvic acid [514-10-3] 302.46 C20H30O2 01.030. L-ABRINE N-a-Methyl-L-tryptophan [526-31-8] 218.26 C12H14N2O2 Merck Index 11,5 01.031. (+)-ABSCISIC ACID [21293-29-8] 264.33 C15H20O4 Merck Index 11,6 01.032. (+/-)-ABSCISIC ACID ABA; Dormin [14375-45-2] 264.33 C15H20O4 Merck Index 11,6 01.002. ABSINTHIN Absinthiin, Absynthin [1362-42-1] 496,64 C30H40O6 Merck Index 12,8 01.033. ACACETIN 5,7-Dihydroxy-4'-methoxyflavone; Linarigenin [480-44-4] 284.28 C16H12O5 Merck Index 11,9 01.287. ACACETIN Apigenin-4´methylester [480-44-4] 284.28 C16H12O5 01.034. ACACETIN-7-NEOHESPERIDOSIDE Fortunellin [20633-93-6] 610.60 C28H32O14 01.035. ACACETIN-7-RUTINOSIDE Linarin [480-36-4] 592.57 C28H32O14 Merck Index 11,5376 01.036. 2-ACETAMIDO-2-DEOXY-1,3,4,6-TETRA-O- a-D-Glucosamine pentaacetate 389.37 C16H23NO10 ACETYL-a-D-GLUCOPYRANOSE 01.037. 2-ACETAMIDO-2-DEOXY-1,3,4,6-TETRA-O- b-D-Glucosamine pentaacetate [7772-79-4] 389.37 C16H23NO10 ACETYL-b-D-GLUCOPYRANOSE> 01.038. 2-ACETAMIDO-2-DEOXY-3,4,6-TRI-O-ACETYL- Acetochloro-a-D-glucosamine [3068-34-6] 365.77 C14H20ClNO8 a-D-GLUCOPYRANOSYLCHLORIDE - 1 - High pure reference substances Phytochem Hochreine Standardsubstanzen for research and quality für Forschung und management Referenzsubstanzen Qualitätssicherung Nummer Name Synonym CAS FW Formel Literatur 01.039.
    [Show full text]
  • A Small Molecular Activator of Cardiac Hypertrophy Uncovered in a Chemical Screen for Modifiers of the Calcineurin Signaling Pathway
    A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway Erik Bush*†, Jens Fielitz‡, Lawrence Melvin*, Michael Martinez-Arnold‡, Timothy A. McKinsey*, Ryan Plichta*, and Eric N. Olson†‡ *Myogen, Incorporated, Westminster, CO 80021; and ‡Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9148 Contributed by Eric N. Olson, January 5, 2004 The calcium, calmodulin-dependent phosphatase calcineurin, regu- ative roles for these proteins in the control of calcineurin activity. lates growth and gene expression of striated muscles. The activity of Overexpression of MCIP1 (also called Down syndrome critical calcineurin is modulated by a family of cofactors, referred to as region 1), for example, suppresses calcineurin signaling (12). In modulatory calcineurin-interacting proteins (MCIPs). In the heart, the contrast, MCIP1 also seems to potentiate calcineurin signaling, MCIP1 gene is activated by calcineurin and has been proposed to as demonstrated by the diminution of calcineurin activity in the fulfill a negative feedback loop that restrains potentially pathological hearts of MCIP1 knockout mice (13). Intriguingly, the MCIP1 calcineurin signaling, which would otherwise lead to abnormal car- gene is a target of NFAT and is up-regulated in response to diac growth. In a high-throughput screen for small molecules capable calcineurin signaling (15), which has been proposed to create a of regulating MCIP1 expression in muscle cells, we identified a unique negative feedback loop that dampens calcineurin activity, which 4-aminopyridine derivative exhibiting an embedded partial structural would otherwise lead to abnormal cardiac growth. motif of serotonin (5-hydroxytryptamine, 5-HT).
    [Show full text]
  • Soy Isoflavone Genistein Inhibits an Axillary Osmidrosis Risk Factor ABCC11: in Vitro Screening and Fractional Approach for ABCC11-Inhibitory Activities in Plant Extracts and Dietary
    nutrients Article Soy Isoflavone Genistein Inhibits an Axillary Osmidrosis Risk Factor ABCC11: In Vitro Screening and Fractional Approach for ABCC11-Inhibitory Activities in Plant Extracts and Dietary Flavonoids 1,2, 2, , 1 1 1 Hiroki Saito y, Yu Toyoda * y , Hiroshi Hirata , Ami Ota-Kontani , Youichi Tsuchiya , Tappei Takada 2 and Hiroshi Suzuki 2 1 Frontier Laboratories for Value Creation, Sapporo Holdings Ltd., 10 Okatome, Yaizu, Shizuoka 425-0013, Japan; [email protected] (H.S.); [email protected] (H.H.); [email protected] (A.O.-K.); [email protected] (Y.T.) 2 Department of Pharmacy, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan; [email protected] (T.T.); [email protected] (H.S.) * Correspondence: [email protected] These authors contributed equally to this work. y Received: 2 July 2020; Accepted: 12 August 2020; Published: 14 August 2020 Abstract: Axillary osmidrosis (AO) is a common chronic skin condition characterized by unpleasant body odors emanating from the armpits, and its aetiology is not fully understood. AO can seriously impair the psychosocial well-being of the affected individuals; however, no causal therapy has been established for it other than surgical treatment. Recent studies have revealed that human ATP-binding cassette transporter C11 (ABCC11) is an AO risk factor when it is expressed in the axillary apocrine glands—the sources of the offensive odors. Hence, identifying safe ways to inhibit ABCC11 may offer a breakthrough in treating AO. We herein screened for ABCC11-inhibitory activities in 34 natural products derived from plants cultivated for human consumption using an in vitro assay system to measure the ABCC11-mediated transport of radiolabeled dehydroepiandrosterone sulfate (DHEA-S—an ABCC11 substrate).
    [Show full text]
  • Hormonal Activation of Genes Through Nongenomic
    HORMONAL ACTIVATION OF GENES THROUGH NONGENOMIC PATHWAYS BY ESTROGEN AND STRUCTURALLY DIVERSE ESTROGENIC COMPOUNDS A Dissertation by XIANGRONG LI Submitted to the Office of Graduate Studies of Texas A&M University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY May 2005 Major Subject: Toxicology HORMONAL ACTIVATION OF GENES THROUGH NONGENOMIC PATHWAYS BY ESTROGEN AND STRUCTURALLY DIVERSE ESTROGENIC COMPOUNDS A Dissertation by XIANGRONG LI Submitted to Texas A&M University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Approved as to style and content by: _______________________________ _______________________________ Stephen H. Safe Weston W. Porter (Chair of Committee) (Member) _______________________________ _______________________________ Robert C. Burghardt Timothy D.Phillips (Member) (Chair of Toxicology Faculty) _______________________________ _______________________________ Kirby C. Donnelly Glen A. Laine (Member) (Head of Department) May 2005 Major Subject: Toxicology iii ABSTRACT Hormonal Activation of Genes through Nongenomic Pathways by Estrogen and Structurally Diverse Estrogenic Compounds. (May 2005) Xiangrong Li, B.S., Wuhan University Chair of Advisory Committee: Dr. Stephen H. Safe Lactate dehydrogenase A (LDHA) is hormonally regulated in rodents, and increased expression of LDHA is observed during mammary gland tumorigenesis. The mechanisms of hormonal regulation of LDHA were investigated in breast cancer cells using a series of deletion and mutant reporter constructs derived from the rat LDHA gene promoter. Results of transient transfection studies showed that the -92 to -37 region of the LDHA promoter was important for basal and estrogen-induced transactivation, and mutation of the consensus CRE motif (-48/-41) within this region resulted in significant loss of basal activity and hormone-responsiveness.
    [Show full text]
  • NIH Public Access Author Manuscript Neuropharmacology
    NIH Public Access Author Manuscript Neuropharmacology. Author manuscript; available in PMC 2014 April 01. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Neuropharmacology. 2013 April ; 67C: 223–232. doi:10.1016/j.neuropharm.2012.09.022. New Insights on Neurobiological Mechanisms underlying Alcohol Addiction Changhai Cui1,*, Antonio Noronha1, Hitoshi Morikawa2, Veronica A. Alvarez3, Garret D. Stuber4, Karen K. Szumlinski5, Thomas L. Kash6, Marisa Roberto7, and Mark V. Wilcox3 1Division of Neuroscience and Behavior, NIAAA/NIH, Bethesda, MD 20892 2Waggoner Center for Alcohol & Addiction Research, University of Texas at Austin, Austin, TX 78712 3Laboratory for Integrative Neuroscience, NIAAA/NIH, Bethesda, MD 20892 4Departments of Psychiatry & Cell biology and Physiology, UNC School of Medicine, University of North Carolina, Chapel Hill, Chapel Hill, NC 27599 5Department of Psychology and Brain Sciences, University of California at Santa Barbara, Santa Barbara, CA 93106-9660 6Department of Pharmacology, UNC School of Medicine, University of North Carolina, Chapel Hill, Chapel Hill, NC 27599 7Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, 10550 N. Torrey Pines Rd., La Jolla, CA 92037 Abstract Alcohol dependence/addiction is mediated by complex neural mechanisms that involve multiple brain circuits and neuroadaptive changes in a variety of neurotransmitter and neuropeptide systems. Although recent studies have provided substantial information on the neurobiological mechanisms that drive alcohol drinking behavior, significant challenges remain in understanding how alcohol-induced neuroadaptations occur and how different neurocircuits and pathways cross- talk. This review article highlights recent progress in understanding neural mechanisms of alcohol addiction from the perspectives of the development and maintenance of alcohol dependence.
    [Show full text]
  • Cross-Talk Between Insulin and Serotonin
    Cross-talk between insulin and serotonin signaling in the brain : Involvement of the PI3K/Akt pathway and behavioral consequences in models of insulin resistance Ioannis Papazoglou To cite this version: Ioannis Papazoglou. Cross-talk between insulin and serotonin signaling in the brain : Involvement of the PI3K/Akt pathway and behavioral consequences in models of insulin resistance. Agricultural sciences. Université Paris Sud - Paris XI, 2013. English. NNT : 2013PA11T039. tel-01171549 HAL Id: tel-01171549 https://tel.archives-ouvertes.fr/tel-01171549 Submitted on 5 Jul 2015 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. UNIVERSITÉ PARIS-SUD ÉCOLE DOCTORALE : "Signalisations et Réseaux intégratifs en Biologie" Laboratoire de Neuroendocrinologie Moléculaire de la Prise Alimentaire DISCIPLINE : Neuroendocrinologie THÈSE DE DOCTORAT Soutenue le 4 juillet 2013 par Ioannis Papazoglou “Cross-talk between insulin and serotonin signaling in the brain: Involvement of the PI3K/Akt pathway and behavioral consequences in models of insulin resistance” “Dialogue entre les voies de signalisation de l’insuline et de la sérotonine dans le cerveau: Implication de la voie PI3K/Akt et conséquences comportementales dans des modèles d’insulino-résistance” Directeur de Thèse Prof. Mohammed Taouis Université Paris-Sud Composition du jury: Présidente Prof.
    [Show full text]
  • European Society for Paediatric Research Annual Meeting Abstracts Bilbao, Spain September 27–30, 2003
    0031-3998/03/5404-0557 PEDIATRIC RESEARCH Vol. 54, No. 4, 2003 Copyright © 2003 International Pediatric Research Foundation, Inc. Printed in U.S.A. EUROPEAN SOCIETY FOR PAEDIATRIC RESEARCH ANNUAL MEETING ABSTRACTS BILBAO, SPAIN SEPTEMBER 27–30, 2003 0008NEO 0011NEO PRESCHOOL OUTCOME IN CHILDREN BORN VERY PREMATURELY EFFICACY OF ERYTHROPOITIN IN PREMATURE INFANTS AND CARED FOR ACCORDING TO NIDCAP Adnan Amin, Daifulah Alzahrani Bjo¨rn Westrup1, Birgitta Bo¨hm1, Hugo Lagercrantz1, Karin Stjernqvist2 Alhada Military Hospital City:Taif, Saudi Arabia 1Neonatal Programme, Dept. of Woman and Child Health, Astrid Lindgren Children’s Hospital, Objective: To identify the effect of early of parentral recombinant human erythropoitin (r-HuEPO) Karolinska Institute, Stockholm, Sweden;2Depts. of Psychology and of Paediatrics, University of and iron administration on blood transfusion requirement of premature infants. Methods: In a Lund, Sweden City: Stockholm and Lund, Sweden controlled clinical trial conducted at the Neonatal Intensive Care Unit, Al-Hada Military Hospital, Background/aim: Care based on the Newborn Individualized Developmental Care and Assess- Taif, Kingdom of Saudi Arabia over a 16 month period. We assigned 20 very low birth weight infants ment Program (NIDCAP) has been reported to exert a positive impact on the development of (VLBW) with gestational age of (mean Ϯ SEM 28.4 Ϯ 0.5 weeks and birth weight of (mean Ϯ SEM prematurely born infants. The aim of the present investigation was to determine the effect of such care 1031 Ϯ 42 gm), to receive either intravenous (r-HuEPO 200 U/kg/day) and iron 1mg/kg/day or on the development at preschool age of children born with a gestational age of less than 32 weeks.
    [Show full text]
  • Natural Compounds with Aromatase Inhibitory Activity: an Update
    Reviews 1087 Natural Compounds with Aromatase Inhibitory Activity: An Update Authors Marcy J. Balunas 1, 2,3, 4, A. Douglas Kinghorn5 Affiliations The affiliations are listed at the end of the article Key words Abstract moter-specific, targeting the breast-specific pro- l" breast cancer ! moters I.3 and II. Recently, numerous natural l" aromatase Several synthetic aromatase inhibitors are cur- compounds have been found to inhibit aromatase l" natural compounds rently in clinical use for the treatment of post- in noncellular, cellular, and in vivo studies. These l" plants menopausal women with hormone-receptor pos- investigations, covering the last two years, as well l" marine organisms l" fungi itive breast cancer. However, these treatments as additional studies that have focused on the may lead to untoward side effects and so the evaluation of natural compounds as promoter- search for new aromatase inhibitors continues, specific aromatase inhibitors or as aromatase in- especially those for which the activity is pro- ducers, are described in this review. Introduction thromboembolism. Overall, the study found that ! AIs provided an increased survival benefit over Breast cancer is one of the leading causes of death other endocrine therapies, with acceptable toxic- in women in developed countries and is a grow- ity profiles. Many physicians have begun pre- ing public health concern in developing countries scribing AIs as a first-line treatment in postmeno- as well [1,2]. Estrogens and the estrogen receptor pausal breast cancer patients [3]. are widely known to play an important role in So if there are already clinically available AIs, why breast cancer development and progression.
    [Show full text]
  • Chapter 1 Introduction to Thyroid Hormone, Thyronamines, Monoamine
    Copyright 2008 by Aaron Nathan Snead ii Acknowledgments Portions of this work have been published elsewhere. Chapter 2 is adapted with the permission of the American Chemical Society from Snead, A.N., Santos, M.S., Seal, R.P., Edwards, R.H., and Scanlan T.S. (2007) Thyronamines inhibit plasma membrane and vesicular monoamine transport. ACS Chem Biol, 2(6), 390-8. Chapter 4 is adapted with permission of Elsevier Ltd. from Snead, A.N., Miyakawa, M., Tan, E.S., and Scanlan T.S. (2008) Trace amine-associated receptor 1 (TAAR1) is activated by amiodarone metabolites. Bioorg Med Chem Lett,18(22), 5920-2. Several Compounds tested for activity with rTAAR1,4 and 6 in Chapters 3 and 4 were synthesized by Motonori Miyakawa (Chapter 4, compounds 2, and 4-8) and Edwin S. Tan (Napthylethyamine, and Chapter 4, compounds 3 and 9). We also thank the Amara S. Lab for the donation of the hNET and hDAT DNA constructs, the Blakely R. Lab for the donation of the hSERT DNA construct, and the Grandy D. Lab for the donation of the r-hTAAR1 cell line. This work was supported by fellowship from the Ford Foundation and the NIH Research Supplement to Promote Diversity in Health-Related Research (A.S.), the PEW Latin American Fellowship (M.S.), the NIMH Postdoctoral Fellowship (R.S.), a grant from the NIMH (R.H.E.), and a grant from the National Institutes of Health (T.S.S.). iii Abstract Exploring the Non-Transcriptional Activity of Thyroid Hormone Derivatives This work is premised on the hypothesis that thyroid hormone may be a substrate for the aromatic L-amino acid decarboxylase (AADC) and that the resulting iodothyronamines would have significant structural and perhaps functional similarity with several biogenic amines including the classical monoamine neurotransmitters.
    [Show full text]
  • WO 2012/092288 A2 5 July 20 12 (05.07.2012) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/092288 A2 5 July 20 12 (05.07.2012) W P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, C07D 311/78 (2006.01) A61P 35/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, A61K 31/352 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, PCT/US201 1/06741 1 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 27 December 201 1 (27. 12.201 1) SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, 61/428,439 30 December 2010 (30. 12.2010) US UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant (for all designated States except US): ONCO- DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, THYREON INC.
    [Show full text]
  • Equisetum Arvense-Derived Ingredients As Used in Cosmetics
    Safety Assessment of Equisetum arvense-derived Ingredients as Used in Cosmetics Status: Scientific Literature Review for Public Comment Release Date: March 20, 2020 Panel Meeting Date: September 14-15, 2020 All interested persons are provided 60 days from the above date (May 19, 2020) to comment on this safety assessment and to identify additional published data that should be included or provide unpublished data which can be made public and included. Information may be submitted without identifying the source or the trade name of the cosmetic product containing the ingredient. All unpublished data submitted to CIR will be discussed in open meetings, will be available at the CIR office for review by any interested party and may be cited in a peer-reviewed scientific journal. Please submit data, comments, or requests to the CIR Executive Director, Dr. Bart Heldreth. The Expert Panel for Cosmetic Ingredient Safety members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D.; Lisa, A. Peterson, Ph.D.; Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Executive Director is Bart Heldreth, Ph.D. This report was prepared by Wilbur Johnson, Jr., M.S., Senior Scientific Analyst. © Cosmetic Ingredient Review 1620 L STREET, NW, SUITE 1200 ◊ WASHINGTON, DC 20036-4702 ◊ PH 202.331.0651 ◊ FAX 202.331.0088 ◊ [email protected] INTRODUCTION The safety of the following 5 Equisetum arvense-derived ingredients as used in cosmetics is reviewed in this scientific literature review.
    [Show full text]